Key result
Microalbuminuria is a significant cardiovascular risk factor in both diabetic and nondiabetic patients, and renin-angiotensin system blockade has demonstrated success in its treatment.
Why the study?
Does renin-angiotensin system blockade reduce microalbuminuria and cardiovascular risk in patients with or without diabetes?
Does renin-angiotensin system blockade reduce microalbuminuria and cardiovascular risk in patients with or without diabetes?
Highlights the importance of screening for and treating microalbuminuria with renin-angiotensin system blockade to reduce cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Supports microalbuminuria screening and RAS blockade in diabetic and nondiabetic patients; leaves open large-scale trial confirmation of CV benefit.
Microalbuminuria, the increase in urinary albumin excretion, has most often been linked with renal disease in diabetic patients. However, accumulating data demonstrate a link between albuminuria and cardiovascular disease in both diabetic and nondiabetic patients, even at very low levels of urinary albumin excretion once considered to be 'normal'. The reasons for the increase in cardiovascular risk may be linked to generalized vascular and endothelial dysfunction, mediated by the renin-angiotensin system and the angiotensin II type 1 receptor. Accordingly, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have demonstrated some success in treating microalbuminuria. With the prevalence of microalbuminuria at around 7% in the general population, and as high as 39% in diabetic patients, reducing and preventing microalbuminuria is becoming of increasing interest in helping to reduce cardiovascular risk. Subsequently, international guidelines have recommended screening for the presence of microalbuminuria in all patients with hypertension, diabetes or both.
No takes yet. Share an insight, caveat, or question.
Menne et al. (2010) conducted a review in Microalbuminuria and cardiovascular risk. Renin-angiotensin system blockade (ACE inhibitors and ARBs) was evaluated. Microalbuminuria is a significant cardiovascular risk factor in both diabetic and nondiabetic patients, and renin-angiotensin system blockade has demonstrated success in its treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: